1. Specialist genetic services help with molecular phenotyping, which combines genetic data, clinical information and biological relevance to determine an individuals’ cancer risk
2. All colorectal cancers should be universally tested for Lynch syndrome
3. New guidelines recommend gene-specific colonoscopic surveillance (2-yearly from 25 years for MLH1/MSH2 and 2-yearly from 35 years for MSH6/PMS2)
Lynch syndrome is an autosomal dominant inherited disorder associated with a high lifetime risk of developing colorectal cancer, accounting for 3–4% of cases.1 Lynch syndrome is caused by germline mutations in mismatch repair genes, most commonly in MLH1, MSH2, MSH6, and PMS2, and rarely in EPCAM. More than 90% of cases are due to mutations in MLH1 or MSH2.1 The mismatch repair pathway recognises and repairs errors that occur during DNA replication, helping to maintain genomic integrity.2 The lifetime risk (to age 70 years) of colorectal cancer among people with Lynch syndrome is 10–47%, dependent on sex and gene mutation.3 Consequently, access to specialist family cancer services and interventions, including high-quality screening and colonoscopic surveillance, is vital to reduce the risk of colorectal cancer incidence and mortality.4
The British Society of Gastroenterology (BSG), Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the UK Cancer Genetics Group (UKCGG) joint guidelines on management of hereditary colorectal cancer have been updated to include information on managing individuals with Lynch syndrome.4 Here, we provide a brief guide to the management of Lynch syndrome.
There are two main routes by which patients with suspected Lynch syndrome are referred to genetic services. Firstly, an asymptomatic patient may have a characteristic family history of Lynch syndrome that needs further evaluation. Secondly, tumour testing following resection in an individual with colorectal cancer might suggest Lynch syndrome. This finding would also prompt referral for asymptomatic relatives if a germline mutation is confirmed.
NICE recommends universal testing for Lynch syndrome in all cases of colorectal cancer,5 which is achieved by immunohistochemistry testing for mutations in mismatch repair genes. In asymptomatic patients presenting with a family history of Lynch syndrome, immunohistochemistry results of an affected relative should be retrieved, or testing requested. Testing of benign polyps is possible but is not current practice.
Immunohistochemistry can be used to identify loss of protein expression associated with a mismatch repair gene. PCR-based testing may be performed for microsatellite instability on tumour DNA. Normal immunohistochemistry implies sporadic colorectal cancer, and further testing for Lynch syndrome is not required unless a polyposis phenotype is suspected. Abnormal immunohistochemistry showing altered MLH1 and/or PMS2 expression suggests Lynch syndrome.
However, as some sporadic (non-Lynch syndrome) tumours can lead to deficiency in the mismatch repair pathway due to acquired somatic genetic changes, somatic testing for differential hallmarks, such as MLH1 hypermethylation, might be necessary before moving to genetic testing .5 When Lynch syndrome is suspected with mismatch repair pathway testing, germline genetic testing can be offered to individuals following the diagnosis of Colorectal cancer. Once confirmed, asymptomatic adult relatives may be offered germline testing, which is typically performed around the time surveillance is initiated.
Patients with confirmed germline pathogenic mismatch repair variants, or those with strongly suspected Lynch syndrome when testing is unavailable, should start colonoscopic surveillance.4 When looking at surveillance versus no surveillance among a cohort of families with Lynch syndrome, regular surveillance was shown to decrease colorectal cancer incidence (6 versus 16 percent) and mortality (8 versus 22 percent).6 The optimum frequency of colonoscopy is yet to be established, but prospective Lynch syndrome surveillance data suggests most (69%) incident colorectal cancers occur more than 2 years from colonoscopy.3 Engel et al found no significant difference in cumulative incidence of colorectal cancer among 2,747 patients with Lynch syndrome assessed at 1 year, 1–2 years, or 2–3 years.7 Thus, assessment every 2 years should be sufficient.
Current evidence supports gene-specific and age-stratified management. Data from the Prospective Lynch Syndrome Database show low incidence of colorectal cancer in patients younger than 25 years. The median age of colorectal cancer diagnosis is higher in patients with MSH6 and PMS2 variants (52 and 54 years, respectively) than in those with MLH1 and MSH2 variants (45 and 44, respectively).8–10 Therefore, surveillance can start from age 25 years in patients with MLH1 or MSH2 variants and from 35 years in those with MSH6 or PMS2 variants. Identification of polyps or colorectal cancer during surveillance should be assessed according to the usual pathways for sporadic cancer, and the standard guidelines should be followed for post-polypectomy or post-cancer resection surveillance. After diagnosis, patients with Lynch syndrome or those with a family history of colorectal cancer may resume colonoscopic surveillance in line with hereditary colorectal cancer guidelines.
Patients with MLH1 or MSH2 mutations are at increased risk of metachronous colorectal cancer and should be considered for subtotal colectomy, especially younger patients. The 10-year cumulative risk of colorectal cancer is 20% in patients managed by standard resection compared to 4% in those who undergo subtotal colectomy.11 However, in older patients, hemicolectomy may be more appropriate given the higher morbidity associated with subtotal colectomy but negligible difference in life- expectancy.12 There is insufficient data to support differing from standard management in patients with MSH6 or PMS2 variants.
Aspirin may be used as a chemoprophylactic agent in patients with Lynch syndrome. In the CAPP2 randomised controlled trial, this approach significantly reduced the risk of colorectal cancer.13 In the per-protocol analysis of 509 patients with Lynch syndrome randomly assigned 600 mg aspirin daily or placebo daily for 2–4 years, at 10-year follow-up aspirin was associated with a protective effect against incident colorectal cancer (hazard ratio 0.41, 95% CI 0.19–0.86, p=0.02). Of interest, there was a negative correlation between aspirin consumption and Lynch syndrome cancer incidence. However, the optimum dose needs to be established, and is being assessed in the CaPP3 trial. Outside clinical trials, patients should be offered low-dose aspirin to reduce the risk of colorectal cancer.4
Patients with Lynch syndrome also have an increased lifetime risk of extracolonic malignancies, including gastric, small bowel, and pancreatic cancers.1,4 Data are insufficient to support surveillance for these cancers outside clinical trials, but screening for Helicobacter pylori and eradication therapy as appropriate are recommended. This is because of the high proportion of intestinal-type gastric cancer associated with Lynch syndrome (up to 79%)14 and the increased bleeding risk with aspirin chemoprophylaxis.
Patients require referral to specialist family cancer services with access to a genetic counsellor and a clinician with experience in hereditary colorectal cancer. These services offer genetic testing, family screening and provide appropriate specialist knowledge for Lynch syndrome with awareness of patient and support organisations.
Lynch syndrome is a hereditary colorectal cancer syndrome that requires early specialist input to improve consistency in management. This approach ensures robust colonoscopic surveillance follow- up and provides individualised treatment in an era of rapidly growing genetic services.
- Jasperson KW, Tuohy MT, Neklason DW, Burt Hereditary and familial colon cancer. Gastroenterology 2010;138:2044-2058.
- Hsieh P, Yamane K, DNA mismatch repair: molecular mechanism, cancer, and Mech Ageing Dev 2008;129:391-407.
- Møller P, Seppälä T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 2017;66:464-472.
- Monahan KJ, Bradshaw N, Dolwani S, et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut 2020;69:411-444.
- National Institute for Health and Care Molecular testing strategies for Lynch syndrome in people with colorectal cancer. Diagnostics guidance [DG27]. 2017. https://www.nice.org.uk/guidance/dg27 (accessed November 1 2019).
- Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal Gastroenterology. 2000. 118(5):829
- Engel C, Vasen HF, Seppälä T, et No difference in colorectal cancer incidence or stage at detection by colonoscopy among 3 countries with different Lynch syndrome surveillance policies. Gastroenterology 2018;155:1400-1409.e2.
- Møller P, Seppälä TT, Bernstein I, et Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 2018;67:1306-1316.
- Ten Broeke SW, van der Klift HM, Tops CMJ, et Cancer risks for PMS2-associated Lynch syndrome. J Clin Oncol 2018;36:2961-2968.
- Bonadona V, Bonaïti B, Olschwang S, et Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305:2304-2310.
- Renkonen-Sinisalo L, Seppälä TT, Järvinen HJ, et al. Subtotal colectomy for colon cancer reduces the need for subsequent surgery in Lynch Dis Colon Rectum 2017;60:792-799.
- De Vos Tot Nederveen Cappel WH, Buskens E, Van Duijvendijk P, et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene Gut 2003;52:1752-1755.
- Burn J, Gerdes AM, MacRae F, et Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011;378:2081-2087.
- Aarnio M, Salovaara R, Aaltonen LA, et Features of gastric cancer in hereditary non- polyposis colorectal cancer syndrome. Int J Cancer 1997;74:551-555.
Dr Benjamin Norton
Gastroenterology Registrar at the Royal London Hospital. He is due to start his ST3 training post in North Central and East London in Autumn. He completed his Masters in Genomic Medicine at Imperial College London where he worked closely with Dr Kevin Monahan, focusing on colonoscopic surveillance in patients with a family history of bowel cancer. Benjamin is interested in obesity and the growing role of the gastroenterologist in obesity care.
Consultant Gastroenterologist at the Family Cancer Clinic in St Mark’s Hospital.He is an Honorary Senior Lecturer Imperial College London where he supervises students undertaking projects into hereditary colorectal cancer. He has a wealth of experience in hereditary colorectal cancer and recently authored the new guidelines on the management of hereditary colorectal cancer.
CPD - Learning Review
To access the survey for CPD associated with this article click the link below.